The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma

Cancer-testis (CT) antigen genes might promote the progression of multiple myeloma (MM). CT antigens may act as diagnostic and prognostic markers in MM, but their expression levels and clinical implications in this disease are not fully understood. This study measured the expression levels of four C...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer 2014-02, Vol.13 (1), p.25-25, Article 25
Main Authors: Zhang, Yao, Bao, Li, Lu, Jin, Liu, Kai-Yan, Li, Jin-Lan, Qin, Ya-Zhen, Chen, Huan, Li, Ling-Di, Kong, Yuan, Shi, Hong-Xia, Lai, Yue-Yun, Liu, Yan-Rong, Jiang, Bin, Chen, Shan-Shan, Huang, Xiao-Jun, Ruan, Guo-Rui
Format: Article
Language:English
Subjects:
Antigen-antibody reactions
Antigens
Antigens, Neoplasm - analysis
Antigens, Neoplasm - genetics
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Bone marrow
Cancer
Care and treatment
Cytogenetics
Development and progression
Diagnosis
Female
Flow Cytometry
Gene expression
Genetic aspects
Grants
Humans
Male
Medical prognosis
Middle Aged
Multiple myeloma
Multiple Myeloma - genetics
Multiple Myeloma - pathology
Plasmids
Prognosis
Real-Time Polymerase Chain Reaction
Stem cells
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer-testis (CT) antigen genes might promote the progression of multiple myeloma (MM). CT antigens may act as diagnostic and prognostic markers in MM, but their expression levels and clinical implications in this disease are not fully understood. This study measured the expression levels of four CT antigen genes in Chinese patients with MM and explored their clinical implications. Real-time quantitative polymerase chain reaction (qPCR) was used to quantify the expression of MAGE-C1/CT7, MAGE-A3, MAGE-C2/CT10 and SSX-2 mRNA in 256 bone marrow samples from 144 MM patients. In the newly diagnosed patients, the positive expression rates were 88.5% for MAGE-C1/CT7, 82.1% for MAGE-C2/CT10, 76.9% for MAGE-A3 and 25.6% for SSX-2. The expression levels and the number of co-expressed CT antigens correlated significantly with several clinical indicators, including the percentage of plasma cells infiltrating the bone marrow, abnormal chromosome karyotypes and the clinical course. MAGE-C1/CT7, MAGE-A3, MAGE-C2/CT10 and SSX-2 expression levels provide potentially effective clinical indicators for the auxiliary diagnosis and monitoring of treatment efficacy in MM.
ISSN:1476-4598
1476-4598
DOI:10.1186/1476-4598-13-25